EIF2B2: A Drug Target and Biomarker for Initiation of Eukaryotic Translation

Target Name: EIF2B2

NCBI ID: G8892

EIF2B2

EIF2B2: A Drug Target and Biomarker for Initiation of Eukaryotic Translation

Eukaryotic translation initiation factor 2B (EIF2B2), also known as subunit 2 beta, is a protein that plays a crucial role in the initiation of protein translation in eukaryotic cells. It is a 39kDa protein that is expressed in most eukaryotic cells and is involved in the process of translation initiation.

The translation of RNA into protein is a critical process that involves the interaction between various cellular components. EIF2B2 is one of the key proteins that plays a vital role in this process. It is an essential protein that helps to establish a favorable environment for the initiation of translation.

One of the key functions of EIF2B2 is its ability to interact with the ribosome, which is the protein machine that reads the genetic code in mRNA and produces the corresponding protein. The interaction between EIF2B2 and the ribosome allows for the formation of a complex that is necessary for the initiation of translation.

In addition to its role in translation initiation, EIF2B2 is also involved in the regulation of translation efficiency. It has been shown to play a role in the regulation of translation rate, as well as the translation of specific target genes.

Despite its importance in the initiation of translation, EIF2B2 is not well understood, and its role in the process is still being explored. There is evidence to suggest that EIF2B2 may be a potential drug target, and research is being conducted to investigate its potential as a therapeutic agent.

One approach that is being used to investigate the potential of EIF2B2 as a drug target is the use of small molecule inhibitors. Researchers have developed a number of compounds that are designed to interact with EIF2B2 and prevent it from interacting with the ribosome. These compounds have been shown to be effective in inhibiting the translation of specific genes, and may be useful as potential therapeutic agents.

Another approach that is being used to investigate the potential of EIF2B2 as a drug target is the use of RNA interference (RNAi) technology. RNAi allows researchers to introduce specific genes into cells and silence their expression, allowing researchers to study the function of EIF2B2 and other genes in the cell.

Research has also been conducted to investigate the role of EIF2B2 in cancer, and the potential of inhibiting its activity as a therapeutic approach for cancer treatment. EIF2B2 has been shown to be involved in the regulation of cell cycle progression and has been implicated in the development of certain types of cancer.

In conclusion, EIF2B2 is a protein that plays a crucial role in the initiation of protein translation in eukaryotic cells. Its role in the process is still being explored, and there is evidence to suggest that it may be a potential drug target or biomarker. Further research is needed to fully understand its function and its potential as a therapeutic agent.

Protein Name: Eukaryotic Translation Initiation Factor 2B Subunit Beta

Functions: Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP

The "EIF2B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF2B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets